A new layer has been added to Walmart’s pending opioid-related litigation, this time with investors going after the company.

In a securities class action suit filed Wednesday in the U.S. District Court for the District of Delaware, an investor alleged executives knowingly padded Walmart Inc.’s pharmacy revenue by encouraging pharmacists to fill opioid prescriptions with questionable legitimacy.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]